| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
DH-8P-DB does not have a specific molecular target clearly defined in the available literature. It is classified as an anticancer candidate that exhibits cytotoxicity against colon cancer cells. As a synthetic flavonoid derivative, it may interact with multiple cellular pathways involved in cancer cell survival and proliferation. Further studies are needed to identify its precise molecular target(s) and mechanism of action.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that DH-8P-DB exhibits cytotoxicity against colon cancer cells. Preliminary studies have shown its potential as an anticancer agent. Detailed in vitro activity data, including IC50 values against specific cancer cell lines, are not extensively documented in the available literature. The compound's activity as a synthetic flavonoid derivative suggests potential interactions with multiple cellular targets.
|
| ln Vivo |
In vivo activity of DH-8P-DB has not been extensively documented in the available literature. As an anticancer candidate with demonstrated in vitro cytotoxicity against colon cancer cells, it may have potential for in vivo efficacy in animal models of colon cancer. Detailed in vivo data, including tumor growth inhibition studies in xenograft models, are not available from the search results.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding assay for DH-8P-DB is not clearly defined in the available literature, as the compound's molecular target has not been identified. As a synthetic flavonoid derivative, it may interact with enzymes or receptors involved in cancer cell survival. Cytotoxicity assays, such as MTT or CCK-8, are used to evaluate its activity against cancer cell lines.
|
| Cell Assay |
In vitro cell-based assays for DH-8P-DB are conducted using colon cancer cell lines. Cells are treated with the compound at various concentrations, and cell viability is measured using MTT, CCK-8, or similar assays. Cytotoxicity is evaluated by determining the IC50 value. Apoptosis induction may be assessed by measuring caspase activation, Annexin V staining, or DNA fragmentation. Standard protocols include appropriate positive controls such as known chemotherapeutic agents.
|
| Animal Protocol |
In vivo animal studies for DH-8P-DB would typically be conducted using xenograft mouse models implanted with colon cancer cells. Tumor-bearing mice would be administered the compound via appropriate routes, and tumor growth inhibition would be monitored. However, detailed in vivo protocols and efficacy data are not available from the search results. The compound is designated for research use only.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of DH-8P-DB include a molecular weight of 374.39 and a molecular formula of C23H18O5. As a synthetic flavonoid derivative, it may have moderate oral bioavailability and metabolic stability. Detailed pharmacokinetic parameters such as half-life, Cmax, and tissue distribution are not extensively documented in the available literature. The compound is intended for research use only.
|
| Toxicity/Toxicokinetics |
Toxicity information for DH-8P-DB is limited. Standard safety precautions for handling research chemicals should be followed. The compound is designated for research use only and is not for human therapeutic applications. Cytotoxicity against cancer cells suggests potential toxicity to normal cells as well, and appropriate safety measures should be taken. No detailed toxicity data are available from the search results.
|
| References | |
| Additional Infomation |
DH-8P-DB is an anticancer candidate that exhibits cytotoxicity against colon cancer cells. It is a synthetic flavonoid derivative with a molecular formula of C23H18O5 and a molecular weight of 374.39 g/mol. The compound has demonstrated cytotoxic activity in preliminary studies. It is intended for research use only and is not for human therapeutic applications.
|
| Exact Mass |
374.115
|
|---|---|
| CAS # |
1054549-71-1
|
| PubChem CID |
102448315
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
28
|
| Complexity |
561
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1C(OC2=C(C(=CC(=C2C1=O)O)O)/C=C/C3=CC=CC=C3)C4=CC=C(C=C4)O
|
| InChi Key |
CCIHCBLYXNADJC-IZZDOVSWSA-N
|
| InChi Code |
InChI=1S/C23H18O5/c24-16-9-7-15(8-10-16)21-13-20(27)22-19(26)12-18(25)17(23(22)28-21)11-6-14-4-2-1-3-5-14/h1-12,21,24-26H,13H2/b11-6+
|
| Chemical Name |
5,7-dihydroxy-2-(4-hydroxyphenyl)-8-[(E)-2-phenylethenyl]-2,3-dihydrochromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Typically soluble in DMSO (e.g. 10 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
